Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | TRPV6 | Q9H1D0 | 5/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3277753 | 0.88 | RECQL (0.62) | SMN1; SMN2RECQLTSHRACHEKMT2A | |
| SCHEMBL4797625 | 0.87 | SIGMAR1 (0.69) | SMN1; SMN2RECQLSIGMAR1TRPV6TSHR | |
| SCHEMBL3709310 | 0.85 | RECQL (0.70) | SMN1; SMN2RECQLSIGMAR1TRPV6TSHR | |
| SCHEMBL7309138 | 0.85 | TSHR (0.52) | SIGMAR1TSHRKMT2ADRD2 | |
| SCHEMBL13943667 | 0.83 | SIGMAR1 (0.64) | SMN1; SMN2RECQLSIGMAR1TRPV6TSHR | |
| Hydrochloric Acid SCHEMBL3706762 | 0.83 | RECQL (0.68) | SMN1; SMN2RECQLSIGMAR1TRPV6TSHR | |
| SCHEMBL2336883 | 0.82 | KDM4E (0.65) | SMN1; SMN2RECQLSIGMAR1TRPV6TSHR | |
| Hydrochloric Acid SCHEMBL2331568 | 0.81 | KDM4E (0.63) | SMN1; SMN2RECQLSIGMAR1TRPV6TSHR | |
| SCHEMBL7621973 | 0.80 | SMN1; SMN2 (0.51) | SMN1; SMN2RECQLSIGMAR1TRPV6TSHR | |
| SCHEMBL2087518 | 0.80 | RECQL (0.60) | SMN1; SMN2RECQLSIGMAR1TRPV6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160193216-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160193216-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160193216-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. | 2016-07-07 | — | — | US | disclosed |
| US-9212190-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212190-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212190-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| EP-2802330-A1 | IRAK INHIBITORS AND USES THEREOF | Nimbus Iris, Inc. (US) | 2014-11-19 | — | — | EP | disclosed |
| WO-2013106535-A9 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2014-09-04 | — | — | WO | disclosed |
| WO-2013106535-A9 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2014-09-04 | — | — | WO | disclosed |
| US-20130231328-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| EP-1023273-B1 | CYCLOHEXANE DERIVATIVES DIFUNCTIONALISED IN 1,4 AS LIGANDS OF 5HT1A RECEPTORS | PF MEDICAMENT (FR) | 2002-06-05 | — | — | EP | disclosed |
| US-6153611-A | AS NON-DOPAMINERGIC ANTIISCHEMIC COMPOUNDS FOR TREATING BRAIN DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-11-28 | — | — | US | disclosed |
| EP-1023273-A1 | CYCLOHEXANE DERIVATIVES DIFUNCTIONALISED IN 1,4 AS LIGANDS OF 5T H1A RECEPTORS | PIERRE FABRE MEDICAMENT (FR) | 2000-08-02 | — | — | EP | disclosed |
| WO-1999020613-A1 | CYCLOHEXANE DERIVATIVES DIFUNCTIONALISED IN 1,4 AS LIGANDS OF 5T H1A RECEPTORS | PIERRE FABRE MEDICAMENT (FR) | 1999-04-29 | — | — | WO | disclosed |
| EP-0546583-B1 | Piperazinyl-and piperidinyl-cyclohexanols | BRISTOL MYERS SQUIBB CO (US) | 1996-05-22 | — | — | EP | disclosed |
| US-5478828-A | Anxiolytic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-12-26 | — | — | US | disclosed |
| EP-0560669-B1 | Piperazinyl-and piperidinyl-cyclohexenes and cyclohexanes | BRISTOL MYERS SQUIBB CO (US) | 1995-06-14 | — | — | EP | disclosed |
| US-5387593-A | Anxiolytic agents | BRISTON-MYERS SQUIBB (US) | 1995-02-07 | — | — | US | disclosed |
| EP-0560669-A1 | Piperazinyl-and piperidinyl-cyclohexenes and cyclohexanes | Bristol-Myers Squibb Company (US) | 1993-09-15 | — | — | EP | disclosed |
| EP-0546583-A1 | Piperazinyl-and piperidinyl-cyclohexanols | Bristol-Myers Squibb Company (US) | 1993-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193216-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SMN1; SMN2 2457/4885RECQL 2685/4885SIGMAR1 3795/4885 |
| US-20130231328-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SMN1; SMN2 2457/4885RECQL 2685/4885SIGMAR1 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.